PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1–positive NSCLC

Mehmet Altan, Vishal Navani, Hye Ryun Kim, Longhua Sun, Luis Paz-Ares, Izabela Chmielewska, Chien-Chung Lin, Kristof Cuppens, Ioannis Mountzios, Nir Peled, Federico Cappuzzo, Bo Wang, Caicun Zhou, Nicolas Girard, Yijia Wang, Sandra T. Asanin, Mo Huang, Edward Garon

Open source

DOI: 10.1080/14796694.2026.2752788
Published: 2026-11-06
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2752788,
  title = {PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1–positive NSCLC},
  author = {Mehmet Altan and Vishal Navani and Hye Ryun Kim and Longhua Sun and Luis Paz-Ares and Izabela Chmielewska and Chien-Chung Lin and Kristof Cuppens and Ioannis Mountzios and Nir Peled and Federico Cappuzzo and Bo Wang and Caicun Zhou and Nicolas Girard and Yijia Wang and Sandra T. Asanin and Mo Huang and Edward Garon},
  year = {2026},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2026.2752788},
  url = {https://doi.org/10.1080/14796694.2026.2752788}
}

RIS

TY  - JOUR
TI  - PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1–positive NSCLC
AU  - Mehmet Altan
AU  - Vishal Navani
AU  - Hye Ryun Kim
AU  - Longhua Sun
AU  - Luis Paz-Ares
AU  - Izabela Chmielewska
AU  - Chien-Chung Lin
AU  - Kristof Cuppens
AU  - Ioannis Mountzios
AU  - Nir Peled
AU  - Federico Cappuzzo
AU  - Bo Wang
AU  - Caicun Zhou
AU  - Nicolas Girard
AU  - Yijia Wang
AU  - Sandra T. Asanin
AU  - Mo Huang
AU  - Edward Garon
PY  - 2026
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2752788
UR  - https://doi.org/10.1080/14796694.2026.2752788
ER  -

APA

Altan, M., Navani, V., Kim, H. R., Sun, L., Paz-Ares, L., Chmielewska, I., Lin, C., Cuppens, K., Mountzios, I., Peled, N., Cappuzzo, F., Wang, B., Zhou, C., Girard, N., Wang, Y., Asanin, S. T., Huang, M., & Garon, E. (2026). PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1–positive NSCLC. Future Oncology. https://doi.org/10.1080/14796694.2026.2752788

Source records

crossref · retrieved 2026-11-08T11:41:51.207Z